CN107802656A - Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated - Google Patents
Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated Download PDFInfo
- Publication number
- CN107802656A CN107802656A CN201610810757.6A CN201610810757A CN107802656A CN 107802656 A CN107802656 A CN 107802656A CN 201610810757 A CN201610810757 A CN 201610810757A CN 107802656 A CN107802656 A CN 107802656A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- inactivation
- acid bacteria
- canine
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 241000894006 Bacteria Species 0.000 title claims abstract description 45
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 41
- 239000004310 lactic acid Substances 0.000 title claims abstract description 41
- 201000010099 disease Diseases 0.000 title claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 35
- 241000282465 Canis Species 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000003612 virological effect Effects 0.000 title claims abstract description 21
- 230000002779 inactivation Effects 0.000 claims abstract description 42
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 14
- 238000010253 intravenous injection Methods 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 8
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 7
- 240000001929 Lactobacillus brevis Species 0.000 claims description 7
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 5
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000701931 Canine parvovirus Species 0.000 claims description 4
- 241000194031 Enterococcus faecium Species 0.000 claims description 4
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 241001052560 Thallis Species 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 208000005252 hepatitis A Diseases 0.000 claims description 4
- 241000711506 Canine coronavirus Species 0.000 claims description 3
- 241001353878 Canine parainfluenza virus Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 3
- 238000001647 drug administration Methods 0.000 claims description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 244000164595 Lactobacillus plantarum subsp plantarum Species 0.000 claims description 2
- 235000012523 Lactobacillus plantarum subsp plantarum Nutrition 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 238000002679 ablation Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 241000192132 Leuconostoc Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract description 2
- 230000000415 inactivating effect Effects 0.000 abstract description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000194035 Lactococcus lactis Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 241001478240 Coccus Species 0.000 description 3
- 208000000655 Distemper Diseases 0.000 description 3
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 description 3
- 208000014058 canine distemper Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000529920 Pediococcus parvulus Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 241001414720 Cicadellidae Species 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241001183079 Lactococcus lactis subsp. hordniae Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241000192134 Oenococcus oeni Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241001552596 Scorzoneroides helvetica Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of new application for inactivating lactic acid bacteria in canine viral disease medicine is prevented and treated, belong to biomedicine field, the main component of medicine is inactivation lactic acid bacteria, can be by the way that lactic acid bacteria living be prepared by conventional method inactivation, inactivation lactic acid bacteria intravenously administrable can be used for prevention, treatment or the auxiliary treatment of the various viral diseases of dog, have broad application prospects.
Description
Technical field
The invention belongs to biomedicine field, more particularly to inactivation lactic acid bacteria are new in canine viral disease medicine is prevented and treated
Purposes.
Background technology
Dog becomes many cade animals as pet, and often with humanoid into deep feelings.What dog often occurred
Some virosis are serious to endanger pet health and affect the emotion of people.The common viral disease of dog includes：Hundstaupe
Heat, canine parvovirus disease, canine coronavirus disease, canine parainfluenza virus disease, rabies, dog pseudoabies, canine infectious hepatitis and
Hepatitis infectiosa canis virus disease etc..At present reply canine viral disease frequently with measure include：Various viral vaccines are inoculated with, but due to virus
Constantly variation and virulence enhancing, vaccine prevention and control also tends to fail；Treated using antiviral chemical drug, such as Ribavirin, adamantane
Amine, abitilguanide etc., but the long-term use of antiviral agent can also make virus produce drug resistance；Anti virus herb and its extract face
Bed application is also wide, such as folium isatidis parenteral solution, Shuanhuanglian injection, Radix Astragali polysaccharide injection, though the antiviral curative effect of Chinese medicine
Definitely, but it also is difficult to reach ideal effect；In addition, also treated using some biological agents, such as interferon, transfer factor, anti-blood
Clearly, immunoglobulin, monoclonal antibody etc., such curative effect of medication is preferable, but because virus variation effect can also decline.
Canine viral disease difficulty of prevention and cure is larger, therefore the medicine for finding new preventing and treating canine viral disease is very heavy
Will.Present invention discover that the lactic acid bacteria of inactivation is carried out into intravenously administrable can effectively prevent and treat the viral disease of dog, at present both at home and abroad
It there is no relevant report.
The content of the invention
The invention provides a kind of brand-new inactivation lactic acid bacteria intravenous injection that can be used for canine viral disease preventing and treating,
The main component of this medicine is the lactic acid bacteria of inactivation, and the various viral diseases that can effectively prevent and treat dog are administered in the medical intravenous
Disease.
Inactivate purposes of the lactic acid bacteria in canine viral disease medicine is prepared, it is characterised in that to described inactivation lactic acid
Bacterium carries out Gram's staining, and in oily Microscopic observation, inactivation lactic acid bacteria keeps complete thalli morphology, and the administering mode of medicine is injection
Administration.The described complete thalli morphology of holding refers to basically identical with the profile of viable bacteria thalline and form before inactivation.Described base
This is consistent substantially to refer to somatic cells wall in lactic acid bacteria inactivation process it is possible that slight change, such as part surface composition
Loss, but this change is very little or seldom generation.
The kinds of lactobacillus of the inactivation lactic acid bacteria intravenous injection of preventing and treating canine viral disease is prepared for the present invention to be included：
(1) lactobacillus：Lactobacillus delbrueckii (L.delbrueckii), lactobacillus bulgaricus (L.bulgaricus), Lactobacillus helveticus
(L.helviticus), lactobacillus acidophilus (L.acido phlus), lactobacillus gasseri (L.gasseri), Lactobacillus salivarius
(L.salivarius), Lactobacillus plantarum (L.plantarum), lactobacillus reuteri (L.reuteri), Lactobacillus brevis
(L.brevis), Lactobacillus casei (L.casei), lactobacillus fermenti (L.fementi) etc.；(2) Pediococcus：Such as lactic acid sheet ball
Bacterium (P.acidi1actic), Pediococcus pentosaceus (P.pentasiaceus), Pediococcus parvulus (P.parvulus) etc.；(3) bright string ball
Pseudomonas：The bright string coccus (L.mesenteroides) of goldbeater's skin and its subsp. cremoris (L.cremoris) and dextranicum
(Leuc.dextranicun), the bright string coccus (L.lactis) of lactic acid, the bright string coccus (L.oenos) of wine etc.；(4) enterococcus spp：
VREF (E.faecium), enterococcus faecalis (E.faecalis) etc.；(5) lactococcus：Lactococcus lactis subsp. lactis
(L.lactis subsp.lactis), lactococcus lactis subsp (L.lactis subsp.cremoris), Lactococcus lactis
Bacterium leafhopper subspecies (L.lactis subsp.hordniae) etc.；(6) streptococcus：Streptococcus lactis (S.lactis), diacetyl
Streptococcus lactis (S.diacetilactis), streptococcus cremoris (S.creamoris), streptococcus thermophilus
(S.thermophilus) etc.；(7) Bifidobacterium：Bifidobacterium bifidum (B.bifidum), bifidobacterium longum
(B.longum), bifidobacterium breve (B.breve), bifidobacterium infantis (B.infantis), bifidobacterium adolescentis
(B.adolescentis), animal bifidobacteria (B.animalis) etc.；(8) lactic acid bacteria of other kinds.
Preferably, lactic acid bacteria is selected from Lactococcus lactis subsp. lactis (latin name：Lactococcus lactis
Subsp.Lactis, deposit number：CICC 6246), Lactobacillus plantarum plant subspecies (latin name：Lactobacillus
Plantarum subsp.Plantarum, deposit number：CICC 6240), bifidobacterium longum (latin name：
Bifidobacterium longum, deposit number：CICC 6196), Lactobacillus brevis (latin name：Lactobacillus
Brevis, deposit number：CICC 6239), VREF (latin name：Enterococcus faecium, deposit number：
CICC 6049)。
Lactic acid bacteria is inactivated as one or more kinds of inactivation mixture of lactic acid bacteria.Inactivated using HTHP, ultraviolet goes out
Any of living, chemical reagent inactivation or radiological inactivation ablation method obtain the inactivation lactic acid bacteria.
During drug administration by injection, it is 10 that the complete thalline quantity of inactivation lactic acid bacteria is included in every ml dose drugs5—1012It is individual.It is described
Powder-injection or mixed suspension injection can be made in preventing and treating canine viral disease medicine.Described drug administration by injection is administered for intravenous injection.
Administering mode for the inactivation lactic acid bacteria intravenous injection of the present invention includes：Intravenous injection and drip-feed etc..
The present invention has inactivated VREF using conventional method, finds the VREF of inactivation and still can carry out gram
The thalline profile and form that dyeing, the VREF of oily Microscopic observation inactivation and the VREF to live are consistent.Then to going out
VREF normal saline suspension living is centrifuged, and is abandoned supernatant and is stayed precipitation, extracts DNA, can still be amplified using round pcr
16s rDNA genetic fragments, kinds of lactobacillus discriminating can also be carried out by sequencing.Further study show that dung intestines ball will be inactivated
Bacterium can effectively prevent and treat canine parvovirus disease and canine distemper to dog intravenously administrable.Illustrating to inactivate lactic acid bacteria intravenously administrable can be with
Preventing and treating for canine viral disease.
The inactivation lactic acid bacteria intravenous injection of the present invention can be used for the preventing and treating of the various viral diseases of dog through intravenously administrable,
Including：Canine distemper, canine parvovirus disease, canine coronavirus disease, canine parainfluenza virus disease, rabies, dog pseudoabies, dog are infected
Property hepatitis and hepatitis infectiosa canis virus disease etc..
The mechanism of inactivation lactic acid bacteria intravenous injection preventing and treating canine viral disease is not fully understood at present, thus it is speculated that possible
Mechanism is：Lactic acid bacteria intravenously administrable is inactivated, may be interacted with virus, blocking virus infected tissue organ；May also
It is through dog organism metabolism to generate antiviral substance after inactivation lactic acid bacteria intravenously administrable；Or can after inactivation lactic acid bacteria intravenously administrable
The immune system of dog is activated, plays antivirus action etc. indirectly.
Embodiment
Embodiment 1
VREF (is purchased from Chinese industrial Microbiological Culture Collection administrative center, latin name：Enterococcus
Faecium, deposit number：CICC 6049) MRS culture mediums are inoculated in, in 37 DEG C of incubator cultures 24 hours, then 3000 leave
The heart 5 minutes, remove culture supernatants and retain precipitation, add sterile saline cleaning precipitation, centrifuge 5 minutes, repeated washing 3 times
Afterwards, sterile saline is added, is mixed with precipitation.A certain amount of VREF normal saline suspension is taken, in spectrophotometer
Its OD value is measured at 690nm, when the OD values of the ultimate density diluted with sterile saline are 0.38, by such diluted concentration
VREF normal saline suspension as 1 times of (1 ×) concentration, carrying out bacteria count through THOMA bateria chambers should
Contain inactivation VREF thalline quantity about 10 under concentration conditions in every ml suspensions8It is individual.This experimental formula dung of 1 × concentration
Enterococcus normal saline suspension.The VREF normal saline suspension of 1 a small amount of × concentration is taken, carries out Gram's staining,
In the form of oily Microscopic observation viable bacteria.Hereafter by the VREF normal saline suspension of the 1 × concentration prepared in 121 DEG C,
Pressure 0.12MPa, 15min is inactivated, obtain inactivating VREF injection, take a small amount of inactivation VREF injection to carry out leather blue
Albert'stain Albert, in the form of oily Microscopic observation inactivation thalline, it is found that inactivation lactic acid bacteria keeps complete thalli morphology, preceding work is inactivated with it
Bacterium thalline profile is consistent with form, and intact bacterial quantity does not have significant change before and after inactivation.
Embodiment 2
Certain pet clinic, the adult dogs for suffering from parvovirus, feeding is reduced, body temperature rise, vomiting, defecation occurs
Number increases symptom, in morbidity early stage.Suspension prepared by embodiment 1 is diluted into 10 × concentration inactivation VREF to be suspended
Liquid, veterinarian attempt using it to treat dog, same day intravenous injection 1mL, second day intravenous injection 0.5mL again.No
The situation of the observation dog of interruption, finding administration, the vomiting of dog, defecation symptom substantially mitigate two days later, and the state of mind is clearly better,
Until rehabilitation.
Embodiment 3
Certain pet clinic, an adult dogs appetite reduce, body temperature rise, burnout, eye nose outflow watery secretion, veterinarian
Canine distemper early stage is diagnosed as, suspension prepared by embodiment 1 is diluted to 10 × concentration inactivation VREF suspension, made
Treated with the inactivation VREF suspension of the concentration, same day intravenous injection 1mL, second day and intravenous injection 1mL.Between not
The situation of disconnected observation dog, it is found that the state of mind of dog after medication three days starts to take a turn for the better, appetite starts to recover, eventual rehabilitation.
Claims (10)
1. inactivate purposes of the lactic acid bacteria in canine viral disease medicine is prepared, it is characterised in that to described inactivation lactic acid bacteria
Gram's staining is carried out, in oily Microscopic observation, inactivation lactic acid bacteria keeps complete thalli morphology, and the administering mode of medicine is to be administered to
Medicine.
2. purposes according to claim 1, it is characterised in that described lactic acid bacteria is selected from lactobacillus, enterococcus spp, galactococcus
Category, Bifidobacterium, Leuconostoc, streptococcus.
3. purposes according to claim 1, it is characterised in that described lactic acid bacteria is selected from Lactococcus lactis subsp. lactis
(latin name：Lactococcus lactis subsp.Lactis, deposit number：CICC 6246), Lactobacillus plantarum plant
Subspecies (latin name：Lactobacillus plantarum subsp.Plantarum, deposit number：CICC 6240), it is long
Bifidobacterium (latin name：Bifidobacterium longum, deposit number：CICC 6196), Lactobacillus brevis (latin name
Claim：Lactobacillus brevis, deposit number：CICC 6239), VREF (latin name：Enterococcus
Faecium, deposit number：CICC 6049).
4. purposes as claimed in claim 1, it is characterised in that inactivation lactic acid bacteria mixes for one or more kinds of inactivation lactic acid bacterias
Compound.
5. purposes according to claim 1, it is characterised in that inactivated using HTHP, ultraviolet inactivation, chemical reagent
Any of inactivation or radiological inactivation ablation method obtain the inactivation lactic acid bacteria.
6. purposes according to claim 1, it is characterised in that powder pin can be made in the preventing and treating canine viral disease medicine
Agent or mixed suspension injection.
7. according to the purposes described in claim any one of 1-6, it is characterised in that described drug administration by injection is given for intravenous injection
Medicine.
8. purposes according to claim 7, it is characterised in that upon injection, inactivation lactic acid is included in every ml dose drugs
The complete thalline quantity of bacterium is 105—1012It is individual.
9. according to the injection described in claim any one of 1-8, it is characterised in that described injection is made as follows
It is standby：After lactic acid bacteria is carried out into conventional liq medium culture 12-36 hours, 3000-5000 leaves the heart and retains precipitation, then will precipitation
Fully after cleaning, required concentration suspensions are configured to, in 120-122 DEG C, pressure 0.1-0.2MPa, inactivation 15-30min is gone out
Live lactobacillus injection.
10. according to the purposes described in claim any one of 1-9, it is characterised in that the canine viral disease includes：Hundstaupe
Heat, canine parvovirus disease, canine coronavirus disease, canine parainfluenza virus disease, rabies, dog pseudoabies, canine infectious hepatitis and
Hepatitis infectiosa canis virus disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610810757.6A CN107802656A (en) | 2016-09-08 | 2016-09-08 | Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610810757.6A CN107802656A (en) | 2016-09-08 | 2016-09-08 | Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107802656A true CN107802656A (en) | 2018-03-16 |
Family
ID=61576115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610810757.6A Pending CN107802656A (en) | 2016-09-08 | 2016-09-08 | Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107802656A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579574A (en) * | 2013-07-12 | 2016-05-11 | 森永乳业株式会社 | Novel lactobacillus and novel lactobacillus-containing medicine, food, beverage and feed |
-
2016
- 2016-09-08 CN CN201610810757.6A patent/CN107802656A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579574A (en) * | 2013-07-12 | 2016-05-11 | 森永乳业株式会社 | Novel lactobacillus and novel lactobacillus-containing medicine, food, beverage and feed |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| de Vos | Fame and future of faecal transplantations–developing next‐generation therapies with synthetic microbiomes | |
| Stringer et al. | Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats | |
| JP2024003162A (en) | New use for treatment of clostridium difficile infections | |
| CN106399141B (en) | A kind of bacteroides fragilis and its application | |
| US20130295054A1 (en) | Modified Bacteria and their Uses thereof for the Treatment of Cancer or Tumor | |
| AU2011276134B2 (en) | Use of parvovirus for eliminating cancer stem cells (CSCs) | |
| Kim et al. | Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3 | |
| Liu et al. | 16S rDNA analysis of the effect of fecal microbiota transplantation on pulmonary and intestinal flora | |
| CN107802653A (en) | Inactivate application of the lactic acid bacteria in tumor disease medicine is prevented and treated | |
| CN107802831A (en) | One kind inactivation lactic acid bacteria vaccine adjuvant | |
| Kosznik-Kwaśnicka et al. | Biological aspects of phage therapy versus antibiotics against Salmonella enterica serovar Typhimurium infection of chickens | |
| Gneusheva et al. | Justification of a synbiotic preparation (“probiotic+ prebiotic”) composition for use in veterinary practice | |
| CN105193860A (en) | Method for application of artificially-cultured vaginal flora transplantation in treating gynecological inflammation | |
| CN104107194A (en) | Making method of human intestinal micro-ecological system | |
| MX2012012372A (en) | Prevention and treatment of gastrointestinal infection in mammals. | |
| CN107802651A (en) | Inactivate application of the lactic acid bacteria in viral disease medicine is prevented and treated | |
| CN107802657A (en) | Inactivate application of the lactic acid bacteria in porcine viral diseases medicine is prevented and treated | |
| CN107802656A (en) | Inactivate application of the lactic acid bacteria in canine viral disease medicine is prevented and treated | |
| CN107802659A (en) | A kind of intravenous injection for strengthening immunologic function | |
| CN106389475A (en) | Applications of Bacteroides fragilis in prevention and/or treatment of meningitis | |
| Chowdhury et al. | Isolation, identification and functional characterization of Escherichia coli as probiotic against Shigella in Bangladesh | |
| WO2023142176A1 (en) | Pharmaceutical composition for intravenous injection, preparation containing same, and preparation method therefor and use thereof | |
| CN107802652A (en) | Inactivate application of the lactic acid bacteria in bacteriosis medicine is prevented and treated | |
| CN107802658A (en) | Inactivate application of the lactic acid bacteria in poultry viral disease medicine is prevented and treated | |
| Matijašić et al. | Survival and in vivo adhesion of human isolates Lactobacillus gasseri LF221 and K7 in weaned piglets and their effects on coliforms, clostridia and lactobacilli viable counts in faeces and mucosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180316 |
|
| RJ01 | Rejection of invention patent application after publication |